Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.5601
-0.0199 (-3.43%)
Jun 3, 2026, 1:57 PM EDT - Market open
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Vistagen Therapeutics stock has a consensus rating of "Hold" and an average price target of $0.97. The average 1-year stock price forecast is 73.18% higher than the current stock price, while the lowest is $0.90 (+60.69%) and the highest is $1.00 (+78.54%).
Price Target: $0.97 (+73.18%)
Analyst Consensus: Hold
* Price targets were last updated on Feb 13, 2026.
Analyst Ratings
The average analyst rating for Vistagen Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 8, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $1 | Hold | Maintains | $1 | +78.54% | Feb 13, 2026 |
| Jefferies | Jefferies | Hold Downgrades $15 → $0.9 | Hold | Downgrades | $15 → $0.9 | +60.69% | Dec 17, 2025 |
| Maxim Group | Maxim Group | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Dec 17, 2025 |
| Lucid Capital | Lucid Capital | Hold Downgrades $19 → $1 | Hold | Downgrades | $19 → $1 | +78.54% | Dec 17, 2025 |
Financial Forecast
Revenue This Year
1.03M
from 486.00K
Increased by 110.91%
Revenue Next Year
250.00K
from 1.03M
Decreased by -75.61%
EPS This Year
-1.77
from -1.67
EPS Next Year
-1.03
from -1.77
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.3M | ||
| Avg | 1.0M | ||
| Low | 800,000 |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 167.5% | ||
| Avg | 110.9% | ||
| Low | 64.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.59 | ||
| Avg | -1.77 | ||
| Low | -1.93 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.